Literature DB >> 3490520

Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics.

C C Sanders, W E Sanders.   

Abstract

The interaction of type I beta-lactamases with diverse beta-lactam compounds representing cephalosporins, cephamycins, penicillins, penams, penems, carbapenems, monobactams, and clavams was examined by using various Enterobacteriaceae and Pseudomonas aeruginosa as sources of the enzymes. The ability of a given drug to reversibly induce beta-lactamase was unrelated to its ability to select mutants stably derepressed for beta-lactamase production. Imipenem was one of the most-potent enzyme inducers, yet it did not select derepressed mutants. Many of the newer cephalosporins were poor enzyme inducers but readily selected derepressed mutants. Resistance to hydrolysis did not predict a drug's inhibitory activity against derepressed mutants. The activity of the penems, penams, and carbapenems was least affected by derepression of beta-lactamase, whereas the activity of anionic cephalosporins and aztreonam was most affected.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490520     DOI: 10.1093/infdis/154.5.792

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  57 in total

Review 1.  Class I beta-lactamases. Induction and derepression.

Authors:  I Phillips; K Shannon
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

2.  AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump.

Authors:  Daniel J Wolter; Nancy D Hanson; Philip D Lister
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

4.  Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae.

Authors:  Dóra Szabó; Fernanda Silveira; Andrea M Hujer; Robert A Bonomo; Kristine M Hujer; Jane W Marsh; Christopher R Bethel; Yohei Doi; Kathleen Deeley; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Emergence of resistance to beta-lactam agents in Pseudomonas aeruginosa with group I beta-lactamases in Spain.

Authors:  K Colom; A Fdz-Aranguiz; E Suinaga; R Cisterna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

6.  Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.

Authors:  Daniel J Wolter; Amber J Schmidtke; Nancy D Hanson; Philip D Lister
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

7.  [Infections due to multidrug-resistant pathogens : Pathogens, resistance mechanisms and established treatment options].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-10       Impact factor: 1.041

8.  Beta-lactam resistance in Aeromonas spp. caused by inducible beta-lactamases active against penicillins, cephalosporins, and carbapenems.

Authors:  J S Bakken; C C Sanders; R B Clark; M Hori
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

9.  Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.

Authors:  D Voutsinas; T Mavroudis; A Avlamis; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

10.  Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.

Authors:  K S Thomson; D A Weber; C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.